Mail

EVFM - Evofem Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

4.7562

+0.0462 (+0.98%)

As of 12:12PM EDT. Market open.

Stock chart is not supported by your current browser

Previous Close	4.7100
Open	4.7000
Bid	4.7500 x 1000
Ask	4.7900 x 900
Day's Range	4.7000 - 4.8137
52 Week Range	1.7920 - 7.2400
Volume	9,028
Avg. Volume	140,462

Market Cap	220.716M
Beta (3Y Monthly)	-0.50
PE Ratio (TTM)	N/A
EPS (TTM)	-3.0040
Earnings Date	Aug 8, 2019 - Aug 12, 2019
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	10.40

Trade prices are not sourced from all markets

All

News

Press Releases

PR Newswire15 days ago
Evofem Biosciences Added to Russell 3000® Index
SAN DIEGO, July 1, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (EVFM) (Evofem), a clinical-stage biopharmaceutical company was added to the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective at the U.S. market open on July 1, 2019, according to a final list of additions posted June 28. "The inclusion of Evofem Biosciences in the Russell 3000 Index is indicative of the company's significant progress and growth.
PR Newswirelast month
Evofem Biosciences Closes $80 Million Financing Transaction with PDL BioPharma and Other Long-time Investors
SAN DIEGO and INCLINE VILLAGE, Nev., June 10, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (EVFM) (Evofem), a clinical-stage biopharmaceutical company, and PDL BioPharma, Inc. (PDLI) (PDL) today announced the closing of the second tranche for $50 million of an aggregate $80 million strategic financing from PDL and existing Evofem investors, Invesco Asset Management, LTD. (Invesco) and Woodford Investment Management (WIM). "This investment from PDL and the support from two long-time investors enables us to execute our commercialization strategy for Amphora® and to prepare for its anticipated launch as the first-in-class Multipurpose Vaginal pH Regulator for hormone-free birth control in the second quarter of 2020, assuming FDA approval," said Saundra Pelletier, CEO of Evofem Biosciences.
Zacks2 months ago
PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts
PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.
PR Newswire2 months ago
Evofem Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference
SAN DIEGO , May 14, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, announced today that its Chief Executive Officer, Saundra Pelletier , will ...
Zacks2 months ago
PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y
PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues
Motley Fool2 months ago
PDL Biopharma Inc (PDLI) Q1 2019 Earnings Call Transcript
PDLI earnings call for the period ending March 31, 2019.
PR Newswire2 months ago
Evofem Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
Management to Host Conference Call at 11:00 a.m. EDT SAN DIEGO , May 7, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical stage biopharmaceutical ...
PR Newswire3 months ago
Evofem Biosciences to Report First Quarter 2019 Results and Provide Corporate Update on May 7, 2019
-- Conference Call Scheduled for 11:00 a.m. EDT -- SAN DIEGO , April 30, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a conference call to discuss financial results and business ...
PR Newswire3 months ago
Evofem Biosciences Announces Last Patient Enrolled for AMPREVENCE, the Phase 2b Sexually Transmitted Infections Trial of Amphora
Top-line Data Expected in the Fourth Quarter of 2019 SAN DIEGO , April 23, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) ("Evofem"), a clinical stage biopharmaceutical company, ...
GlobeNewswire3 months ago
STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Evofem Biosciences, Inc. – EVFM
NEWTOWN SQUARE, Pa., April 16, 2019 -- Kaskela Law LLC is investigating Evofem Biosciences, Inc. (“Evofem” or the “Company”) (NASDAQ: EVFM) on behalf of the Company’s.
PR Newswire3 months ago
PDL BioPharma Announces Equity Investment in Evofem Biosciences
INCLINE VILLAGE, Nev., April 11, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (PDLI) announces that it has entered into a securities purchase agreement with Evofem Biosciences, Inc. ("Evofem") (EVFM), pursuant to which it will invest a total of up to $60 million in a private placement of securities. The transaction is expected to have two tranches. The first tranche comprises $30 million, which was provided today. In addition, PDL has the right to invest an additional $30 million in a second tranche alongside two existing Evofem shareholders, which have the right to invest up to $10 million each.
PR Newswire3 months ago
Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma
"Successful completion of this financing should enable us to execute our strategy with confidence and to ensure the successful launch of Amphora in 2020 as a novel, hormone-free, woman-controlled contraceptive, if approved by the FDA," said Saundra Pelletier, CEO of Evofem Biosciences.
PR Newswire3 months ago
Evofem Biosciences to Present at Needham Healthcare Conference
SAN DIEGO, Calif. , April 3, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, announced today it will present at the 18 th Annual Needham Healthcare ...
PR Newswire4 months ago
Evofem Biosciences to Present at Upcoming Investor Conferences
SAN DIEGO , March 12, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company, announced today it will ...
Thomson Reuters StreetEvents4 months ago
Edited Transcript of EVFM earnings conference call or presentation 1-Mar-19 4:00pm GMT
Q4 2018 Evofem Biosciences Inc Earnings Call
PR Newswire5 months ago
Evofem Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
Positive Phase 3 Amphora Results Enabling NDA Submission Management to Host Conference Call at 11:00 a.m. EST SAN DIEGO , March 1, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" ...
PR Newswire5 months ago
Evofem Biosciences to Report Fourth Quarter and Year-end 2018 Results and Provide Corporate Update on March 1, 2019
-- Conference Call Scheduled for 11:00 a.m. EST -- SAN DIEGO , Feb. 19, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a conference call to discuss financial results and business ...
ACCESSWIRE6 months ago
Evofem Biosciences, Amphora a Potential New Birth Control, Analysts Review and Target
NEW YORK, NY / ACCESSWIRE / January 7, 2019 / Traders News Source, aleading independent equity research and corporate access firm focused on smalland mid-cap public companies is issuing a comprehensive ...
PR Newswire6 months ago
Evofem Biosciences Provides Corporate Update and Announces Upcoming Milestones
The Company recently reported that its Phase 3 trial evaluating Amphora® for the prevention of pregnancy met its primary endpoint, and plans to resubmit the Amphora NDA in the second quarter of 2019.
Thomson Reuters StreetEvents6 months ago
Edited Transcript of EVFM earnings conference call or presentation 7-Nov-18 4:00pm GMT
Q3 2018 Evofem Biosciences Inc Earnings Call
Zacks7 months ago
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte
Zacks7 months ago
Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY
A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.
Zacks7 months ago
Evofem Shares Up as Birth Control Gel Succeeds in Phase III
Evofem (EVFM) stock surges on positive results from a late-stage study on experimental birth control vaginal gel.
ACCESSWIRE7 months ago
Today's Research Reports on Trending Tickers: Evofem Biosciences and Diffusion Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Evofem Biosciences had a day of gains on Monday after announcing positive results on its hormone free birth control gel. Shares of Diffusion Pharmaceuticals were in the red despite announcing that the company was awarded a patent for the use of its breakthrough drug, trans sodium crocetinate (TSC), in conjunction with Tissue Plasminogen Activator (tPA) for the treatment of stroke.